



Clinical trial results:

Study on the pharmacokinetic interaction between cabazitaxel and darolutamide in metastatic castration-resistant prostate cancer (mCRPC) patients.

Summary

EudraCT number	2020-000823-38
Trial protocol	NL
Global end of trial date	10 November 2021

Results information

Result version number	v1 (current)
This version publication date	15 December 2023
First version publication date	15 December 2023
Summary attachment (see zip file)	publication (Buck et al. Influence of Darolutamide on Cabazitaxel Systemic Exposure.pdf)

Trial information

Trial identification

Sponsor protocol code	CABADARO
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Erasmus MC
Sponsor organisation address	Dr Molewaterplein 40, Rotterdam, Netherlands,
Public contact	A.H.J. Mathijssen, Erasmus MC Cancer Institute, a.mathijssen@erasmusmc.nl
Scientific contact	A.H.J. Mathijssen, Erasmus MC Cancer Institute, a.mathijssen@erasmusmc.nl

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 November 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	10 November 2021
Global end of trial reached?	Yes
Global end of trial date	10 November 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine the influence of darolutamide on the pharmacokinetics of cabazitaxel compared to cabazitaxel alone in mCRPC patients.

Protection of trial subjects:

na

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 October 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 20
Worldwide total number of subjects	20
EEA total number of subjects	20

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	9
From 65 to 84 years	11
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

1. Age \geq 18 years;
2. Patients with a confirmed diagnosis of mCRPC with an indication for cabazitaxel treatment at the standard dose of 20 mg/m².
3. WHO performance \leq 1 (see appendix B).
4. Able and willing to sign the Informed Consent Form

Pre-assignment

Screening details:

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

1. Age \geq 18 years;
2. Patients with a confirmed diagnosis of mCRPC with an indication for cabazitaxel treatment at the standard dose of 20 mg/m².
3. WHO performance \leq 1 (see appendix B).
4. Able and willing to sign the Informed Consent Form

Period 1

Period 1 title	Caba
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	All patients
-----------	--------------

Arm description:

Each patient is its own control

Arm type	All patients
Investigational medicinal product name	Cabazitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

20mg/m² BSA

Number of subjects in period 1	All patients
Started	20
Completed	20

Period 2

Period 2 title	Caba + daro
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	All patients
Arm description: Each patient is its own control	
Arm type	All patients
No investigational medicinal product assigned in this arm	

Number of subjects in period 2^[1]	All patients
Started	18
Completed	18

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: This is inherent to the study design. Each patient is its own control.

Baseline characteristics

Reporting groups

Reporting group title	Caba
-----------------------	------

Reporting group description: -

Reporting group values	Caba	Total	
Number of subjects	20	20	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	11	11	
From 65-84 years	9	9	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	0	0	
Male	20	20	

Subject analysis sets

Subject analysis set title	Caba concentrations
----------------------------	---------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Caba concentrations

Subject analysis set title	Caba concentrations with daro
----------------------------	-------------------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Caba concentrations with daro

Reporting group values	Caba concentrations	Caba concentrations with daro	
Number of subjects	18	18	
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	11		

From 65-84 years	9		
85 years and over	0		

Gender categorical			
Units: Subjects			
Female	0		
Male	20		

End points

End points reporting groups

Reporting group title	All patients
Reporting group description: Each patient is its own control	
Reporting group title	All patients
Reporting group description: Each patient is its own control	
Subject analysis set title	Caba concentrations
Subject analysis set type	Full analysis
Subject analysis set description: Caba concentrations	
Subject analysis set title	Caba concentrations with daro
Subject analysis set type	Full analysis
Subject analysis set description: Caba concentrations with daro	

Primary: Caba concentrations

End point title	Caba concentrations
End point description:	
End point type	Primary
End point timeframe: day 1 vs after 6 weeks	

End point values	Caba concentrations	Caba concentrations with daro		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	18	18		
Units: ng/mL*h				
geometric mean (geometric coefficient of variation)	173 (\pm 26)	165 (\pm 27)		

Statistical analyses

Statistical analysis title	paired t-test on log transformed data
Statistical analysis description: paired t-test on log transformed data	
Comparison groups	Caba concentrations v Caba concentrations with daro

Number of subjects included in analysis	36
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	< 0.05
Method	t-test, 2-sided
Parameter estimate	Mean difference (final values)

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

NA

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	2
--------------------	---

Frequency threshold for reporting non-serious adverse events: 5 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: This was not recorded in this study as per the study protocol

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/35895277>